There are few companies out there with an unblemished track record of annual dividend increases that also have pristine financials to ensure that the dividend raises will continue.
Johnson & Johnson (NYSE: JNJ) is unquestionably one of them.
The company has raised its dividend annually since it began paying one in 1972. Last year marked the 50th year in a row that the drug and consumer products company lifted the dividend.
That’s what you call an impressive track record.
Okay, so the dividend-paying history is superb. But so is its cash flow growth.
In 2021, the maker of Band-Aids, medical devices and cancer-fighting drugs, along with many other products, generated $19.8 billion in free cash flow. That figure is expected to grow to $22.9 billion when Johnson & Johnson reports full-year 2022 results and rocket to $26.7 billion this year.
The company is forecast to have paid out $11.5 billion in dividends in 2022, just 50% of its free cash flow. If the 2023 free cash flow and dividends paid projections are correct, this year, the company’s payout ratio will dip to 45%.
I like to see a company’s payout ratio below 75%. So 45% is quite low and suggests the company has lots of room to raise the dividend even if free cash flow isn’t as strong as predicted.
Johnson & Johnson’s dividend is as safe as a bet that most New Year’s resolutions will be forgotten by February.
Dividend Safety Rating: A
— Marc Lichtenfeld
The Ultimate Dividend Package [sponsor]
Marc Lichtenfeld – renowned income expert and author of Get Rich with Dividends – is giving away his Ultimate Dividend Package – completely free of charge.
Seriously… no credit card required. You’ll get his top dividend picks and favorite strategies… and the chance to collect massive income while you enjoy life!
Claim your FREE Ultimate Dividend Package.
Source: Wealthy Retirement